SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence

References

• Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009;31:2608–2617.
   PubMed Web of Science ®Google Scholar
• De Nicola L, Gabbai FB, Liberti ME, et al. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis. 2014;64:16–24.
   PubMed Web of Science ®Google Scholar
• Murphy D, McCulloch CE, Lin F, et al. Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med. 2016;165:473–481.
   PubMed Web of Science ®Google Scholar
• Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24:302–308.
   PubMed Web of Science ®Google Scholar
• Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518–2531.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Hwang BH, Choi IJ, et al. A prospective two-center study on the associations between microalbuminuria, coronary atherosclerosis and long-term clinical outcome in asymptomatic patients with type 2 diabetes mellitus: evaluation by coronary CT angiography. Int J Cardiovasc Imaging. 2015;31:193–203.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–426.
   PubMed Web of Science ®Google Scholar
• World Health Organization [Internet]. Global report on diabetes; 2016 cited 2018 Jul 9; Available from: http://www.who.int/diabetes/global-report/en/
   Google Scholar
• Corriere M, Rooparinesingh N, Kalyani RR. Epidemiology of diabetes and diabetes complications in the elderly: an emerging public health burden. Curr Diab Rep. 2013;13:805–813.
   PubMed Web of Science ®Google Scholar
• Saran R, Robinson B, Abbott KC, et al. US renal data system 2017 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2018;71:S1–S672.
   PubMed Web of Science ®Google Scholar
• Vupputuri S, Kimes TM, Calloway MO, et al. The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. J Diabetes Complications. 2014;28:10–16.
   PubMed Web of Science ®Google Scholar
• Mujais SK, Story K, Brouillette J, et al. Health-related quality of life in CKD patients: correlates and evolution over time. Clin J Am Soc Nephrol. 2009;4:1293–1301.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Chaudhari P, Yang H, et al. Healthcare resource use, costs, and disease progression associated with diabetic nephropathy in adults with type 2 diabetes: a retrospective observational study. Diabetes Ther. 2017;8:555–571.
   PubMed Web of Science ®Google Scholar
• Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159–169.
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Stenlof K, Leiter LA, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58:1183–1187.
   PubMed Web of Science ®Google Scholar
• Roden M, Merker L, Christiansen AV, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14:154.
   PubMed Web of Science ®Google Scholar
• Stenlof K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014;30:163–175.
   PubMed Web of Science ®Google Scholar
• Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420–428.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes - 2019. Diabetes Care. 2019;42:S90–S102.
   PubMed Web of Science ®Google Scholar
• Sjostrom CD, Johansson P, Ptaszynska A, et al. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diab Vasc Dis Res. 2015;12:352–358.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [Internet]. Highlights of prescribing information: FARXIGA®; 2014 cited 2018 Jul 31. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202293s012lbl.pdf
   Google Scholar
• US Food and Drug Administration [Internet]. Highlights of prescribing information: INVOKANA®; 2017 cited 2018 Jul 31. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204042s026lbl.pdf
   Google Scholar
• US Food and Drug Administration [Internet]. Highlights of prescribing information: JARDIANCE®; 2018 cited 2019 Jan 31. Available from: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf
   Google Scholar
• US Food and Drug Administration [Internet]. Highlights of prescribing information: STEGLATRO®; 2018 cited 2019 Jan 17. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209803s001lbl.pdf
   Google Scholar
• US Food and Drug Administration [Internet]. Highlights of prescribing information: INVOKANA®; 2018 cited 2019 Jan 10. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204042s027lbl.pdf
   Google Scholar
• Heerspink HJL, Kosiborod M, Inzucchi SE, et al. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018;94:26–39.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008;14:782–790.
   PubMedGoogle Scholar
• DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14:5–14.
   PubMed Web of Science ®Google Scholar
• Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60:215–225.
   PubMed Web of Science ®Google Scholar
• Wang MY, Yu X, Lee Y, et al. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes. Proc Natl Acad Sci USA. 2017;114:6611–6616.
   PubMed Web of Science ®Google Scholar
• Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–274.
   PubMed Web of Science ®Google Scholar
• Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255–270.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet. 2015;54:691–708.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53:213–225.
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Lacreta F, et al. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014;53:17–27.
   PubMed Web of Science ®Google Scholar
• Lamos EM, Younk LM, Davis SN. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013;9:763–775.
   PubMed Web of Science ®Google Scholar
• Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int. 2011;80:17–28.
   Google Scholar
• Zhang L, Zhang M, Lv Q, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2018;140:295–303.
   PubMed Web of Science ®Google Scholar
• Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–971.
   PubMed Web of Science ®Google Scholar
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16:1016–1027.
   PubMed Web of Science ®Google Scholar
• Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369–384.
   PubMed Web of Science ®Google Scholar
• Grunberger G, Camp S, Johnson J, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2018;9:49–66.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [Internet]. Risk evaluation and mitigation strategies (REMS) review: NDA 202293 (dapagliflozin tablets, 5 and 10 mg); 2011 cited 2018 Jul 5. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000RiskR.pdf
   Google Scholar
• US Food and Drug Administration [Internet]. Risk evaluation and mitigation strategies (REMS) review: NDA 204042 (canagliflozin tablets, 100 and 300 mg); 2013 cited 2018 Jul 5. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000RiskR.pdf
   Google Scholar
• US Food and Drug Administration [Internet]. FDA drug safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR); 2016 cited 2018 Jul 31. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm505860.htm
   Google Scholar
• Seidu S, Kunutsor SK, Cos X, et al. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis. Prim Care Diabetes. 2018;12:265–283.
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–950.
   PubMed Web of Science ®Google Scholar
• Takashima H, Yoshida Y, Nagura C, et al. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: a randomized open-label prospective trial. Diab Vasc Dis Res. 2018;15:469–472.
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–597.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Porrini EL, Gaspari F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012;35:2061–2068.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6:691–704.
   PubMed Web of Science ®Google Scholar
• Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety cardiovascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206:11–23.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [Internet]. FDA news release: FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes; 2016 cited 2017 Mar 8. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm
   Google Scholar
• Wanner C, Inzucchi SE, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:1801–1802.
   PubMed Web of Science ®Google Scholar
• Verma S, Mazer CD, Fitchett D, et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial. Diabetologia. 2018;61:1712–1723.
   PubMed Web of Science ®Google Scholar
• Verma S, Mazer CD, Al-Omran M, et al. Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation. 2018;137:405–407.
   PubMed Web of Science ®Google Scholar
• Wanner C, Heerspink HJL, Zinman B, et al. Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial. J Am Soc Nephrol. 2018;29:2755–2769.
   PubMed Web of Science ®Google Scholar
• Mordi NA, Mordi IR, Singh JS, et al. Renal and cardiovascular effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop diuretics in diabetic patients with chronic heart failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. BMJ Open. 2017;7:e018097.
   PubMed Web of Science ®Google Scholar
• Rastogi A, Bhansali A. SGLT2 inhibitors through the windows of EMPA-REG and CANVAS trials: a review. Diabetes Ther. 2017;8:1245–1251.
   PubMed Web of Science ®Google Scholar
• Neuen BL, Ohkuma T, Neal B, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function: data from the CANVAS Program. Circulation. 2018;138:1537–1550.
   PubMed Web of Science ®Google Scholar
• Fioretto P, Stefansson BV, Johnsson E, et al. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia. 2016;59:2036–2039.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018. Epub ahead of print. DOI:10.1056/NEJMoa1812389.
   Web of Science ®Google Scholar
• AstraZeneca [Internet]. Study to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure (Dapa-HF). ClinicalTrials.gov record: NCT03036124; 2018 cited 2018 Jul 31. Available from: https://clinicaltrials.gov/ct2/show/NCT03036124?term=NCT03036124
   Google Scholar
• Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:610–621.
   PubMed Web of Science ®Google Scholar
• Hung SC, Kuo KL, Peng CH, et al. Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease. Kidney Int. 2014;85:703–709.
   PubMed Web of Science ®Google Scholar
• Ceriello A, Genovese S, Mannucci E, et al. Glucagon and heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol. 2016. DOI:10.1186/s12933-016-0440-3.
   Web of Science ®Google Scholar
• Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014. DOI:10.1186/1475-2840-13-28.
   PubMed Web of Science ®Google Scholar
• Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17:1180–1193.
   PubMed Web of Science ®Google Scholar
• Lambers Heerspink HJ, de Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853–862.
   PubMed Web of Science ®Google Scholar
• Jardine MJ, Mahaffey KW, Neal B, et al. The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol. 2017;46:462–472.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals Inc. [Internet]. Phase 3 CREDENCE renal outcomes trial of INVOKANA® (canagliflozin) is being stopped early for positive efficacy findings; 2018 cited 2018 Jul 30. Available from: https://www.janssen.com/phase-3-credence-renal-outcomes-trial-invokanar-canagliflozin-being-stopped-early-positive-efficacy
   Google Scholar
• AstraZeneca [Internet]. A study to evaluate the effect of dapagliflozin with and without saxagliptin on albuminuria, and to investigate the effect of dapagliflozin and saxagliptin on HbA1c in patients with type 2 diabetes and CKD. ClinicalTrials.gov record: NCT02547935; 2018 cited 2018 Jul 31. Available from: https://clinicaltrials.gov/ct2/show/NCT02547935?term=NCT02547935
   Google Scholar
• AstraZeneca [Internet]. A study to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease (Dapa-CKD). ClinicalTrials.gov record: NCT03036150; 2018 cited 2018 Jul 31. Available from: https://clinicaltrials.gov/ct2/show/NCT03036150?term=NCT03036150
   Google Scholar
• Boehringer Ingelheim [Internet]. Empagliflozin outcome trial in patients with chronic heart failure with reduced ejection fraction (EMPEROR-Reduced). ClinicalTrials.gov record: NCT03057977; 2018 cited 2018 Jul 31. Available from: https://clinicaltrials.gov/ct2/show/NCT03057977?term=NCT03057977
   Google Scholar
• Boehringer Ingelheim [Internet]. Empagliflozin outcome trial in patients with chronic heart failure with preserved ejection fraction (EMPEROR-Preserved). ClinicalTrials.gov record: NCT03057951; 2018 cited 2018 Jul 31. Available from: https://clinicaltrials.gov/ct2/show/NCT03057951?term=NCT03057951
   Google Scholar
• Boehringer Ingelheim [Internet]. Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of empagliflozin in people with chronic kidney disease; 2018 cited 2018 Apr 16. Available from: https://www.boehringer-ingelheim.com/EMPA-KIDNEY
   Google Scholar
• Boehringer Ingelheim [Internet]. EMPA-KIDNEY (the study of heart and kidney protection with empagliflozin). ClinicalTrials.gov record: NCT03594110; 2018 cited 2018 Jul 31. Available from: https://www.clinicaltrials.gov/ct2/show/record/NCT03594110?view=record
   Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the american association of clinical endocrinologists and American College of endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary. Endocr Pract. 2018;24:91–120.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Microvascular complications and foot care: standards of medical care in diabetes - 2019. Diabetes Care. 2019;42:S124–S138.
   PubMed Web of Science ®Google Scholar
• Weber MA, Mansfield TA, Cain VA, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4:211–220.
   PubMed Web of Science ®Google Scholar